Galapagos Revenue and Competitors

Mechelen,

Location

$5.4B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Galapagos's estimated annual revenue is currently $526.2M per year.(i)
  • Galapagos's estimated revenue per employee is $363,900
  • Galapagos's total funding is $5.4B.
  • Galapagos's current valuation is $3.6B. (January 2022)

Employee Data

  • Galapagos has 1446 Employees.(i)
  • Galapagos grew their employee count by -9% last year.

Galapagos's People

NameTitleEmail/Phone
1
Project Leader, VPReveal Email/Phone
2
Head Biometrics, VPReveal Email/Phone
3
CFO & COOReveal Email/Phone
4
CEOReveal Email/Phone
5
CFO and COOReveal Email/Phone
6
Chief StaffReveal Email/Phone
7
Head Medical WritingReveal Email/Phone
8
Procurement OfficerReveal Email/Phone
9
Head QM R&D ImmunologyReveal Email/Phone
10
VP Late Development PortfolioReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.6M66N/AN/AN/A
Add Company

What Is Galapagos?

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos? pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing promising patient results in, respectively, inflammatory diseases, idiopathic fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people?s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 675 employees, operating from its Mechelen, Belgium headquarters and facilities in the Netherlands, France, Switzerland, the USA and Croatia. More information at www.glpg.com.

keywords:N/A

$5.4B

Total Funding

1446

Number of Employees

$526.2M

Revenue (est)

-9%

Employee Growth %

$3.6B

Valuation

N/A

Accelerator

Galapagos News

2022-04-19 - Has Galapagos (GLPG) Outpaced Other Medical Stocks This Year?

Here is how Galapagos NV (GLPG) and MedAvail Holdings, Inc. (MDVL) have performed compared to their sector so far this year.

2022-04-19 - In the Galápagos, training community scientists to monitor water quality | Penn Today

Both dense human populations and a plethora of wildlife can pose a challenge to marine and public health in the Galápagos Islands.

2022-04-17 - Boat carrying unspecified amount of diesel fuel sinks off Galapagos Islands

A boat carrying barrels of diesel fuel has sank near one of Ecuador's ecologically sensitive Galapagos Islands, according to officials.

2021-09-21 - Galapagos : N.V., - Galapagos increases share capital through subscription right exercises

Galapagos increases share capital through subscription right exercises Mechelen, Belgium; 20 September 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 7,600 new ordina ...

2021-09-17 - Galapagos : N.V., - GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS Mechelen, Belgium; 17 September 2021; 13.15 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Medicines Agency's (EM ...